One damaged spot isn't the same as joint wear

One damaged spot often follows an injury

A twist or fall can harm one patch of cartilage, the smooth cap on each bone end. You'll often remember the twist that began the soreness. Swelling or catching may begin that day.

Wear builds slowly instead of starting on one day. Sitting may leave you stiff, while activity brings more aching. It doesn't stop with the cartilage alone.

An exam connects the knee damage with your soreness

An X-ray shows the joint, but it can't measure how you feel. Some worn-looking knees don't cause much trouble. Other knees ache even when an X-ray shows less wear.

During a QC Kinetix visit, medical providers examine how your knee moves. The clinic calls its non-surgical knee shots regenerative treatments. The shot is called PRP, or platelet-rich plasma.

A small blood sample goes into a spinning machine. That step collects more platelets, which help blood clot and take part in healing. A provider puts the prepared sample into your knee.

Gentle movement can help a knee worn over time

Easy strengthening can steady the muscles around your knee. Short walks may keep it moving without causing a hard flare. Weight loss may lower strain when that applies to you.

Heat can ease stiffness, and ice can settle swelling after activity. You can split chores into smaller parts and rest between them. A cane or rail may help when balance feels unsure.

An X-ray alone can't tell how much a knee hurts

People often ask whether more cartilage always means less soreness. It doesn't, because an X-ray and daily comfort don't always match. The X-ray can't decide whether care helped you.

Notice whether walking, sleep, and chores become easier instead. A provider can record those changes at later visits. Those daily facts give you a clearer way to judge care.

Sources

1. A concise review of mesenchymal stem cells for functional cartilage tissue engineering sets out the underlying problem: articular cartilage is avascular and has very limited intrinsic repair capacity, which is precisely why engineered and cell-based approaches are being pursued - and why building tissue that matches native articular cartilage in composition and mechanical function remains an unsolved engineering problem rather than a delivered clinical product.

   Tan AR, et al. — Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.16-0271.

2. A systematic review of the discordance between clinical and radiographic knee osteoarthritis: many people with severe-looking x-rays have little pain, and many with disabling pain have modest radiographic change. This is the reason a post-treatment scan is a poor proxy for how someone feels, in either direction.

   Bedson J, et al. — The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature.. BMC musculoskeletal disorders, 2008. DOI: 10.1186/1471-2474-9-116.

3. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, 2024.

4. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

5. Eighty patients with a single symptomatic chronic femoral condyle cartilage defect were randomized to autologous chondrocyte implantation or microfracture and followed 14-15 years. No significant difference in clinical scores emerged at long-term follow-up; there were 17 failures in the ACI group versus 13 in the microfracture group and more total knee replacements after ACI (6 versus 3). Fifty-seven percent of surviving ACI patients and 48% of surviving microfracture patients had radiographic early osteoarthritis (KL >=2).

   Knutsen G, et al. — A Randomized Multicenter Trial Comparing Autologous Chondrocyte Implantation with Microfracture: Long-Term Follow-up at 14 to 15 Years.. The Journal of bone and joint surgery. American volume, 2016. DOI: 10.2106/JBJS.15.01208.